180 Life Sciences Corp. to Present at the H.C. Wainwright Bioconnect 2021 Conference
The presentation will be available on-demand through the Conference from January 11-14, 2021 starting at 6:00 a.m. ET.A webcast of the presentation will also be available at the following link: https://journey.ct.events/view/479a72c6-8d48-4a89-b6ba-07b08d34cee1, and in the IR section of the Company’s website. The webcast will be archived and accessible on the website for at least 90 days.About 180 Life Sciences Corp.180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials.Forward-Looking StatementsInvestors:Jason Assad
Director of IR
180 Life Sciences Corp
678-570-6791
Jason@180lifesciences.comMedia Relations:David Schull
David.Schull@russopartnersllc.com
(212) 845-4271Eric Ando
Eric.Ando@russopartnersllc.com
(646) 218-4604